Un abrazo a los que renegaban de la inmunización universal con nirsevimab contra el VRS.
Miles de bebés evitaron el hospital desde 2023. ¿Por qué no lo sabías? 👇
La bronquiolitis mandaba al hospital al 2% de los recién nacidos.
Ya no. España los inmunizó con un anticuerpo y mirad: ¡sus ingresos cayeron un 75%!
La bronquiolitis mandaba al hospital al 2% de los recién nacidos.
Ya no. España los inmunizó con un anticuerpo y mirad: ¡sus ingresos cayeron un 75%!
October 26, 2025 at 1:52 PM
Un abrazo a los que renegaban de la inmunización universal con nirsevimab contra el VRS.
Good news!
Two studies show more promising results for RSV drug nirsevimab (Beyfortus) buff.ly/4ikJ1ox
Phase 3 randomized clinical trial (MELODY) buff.ly/4ignwVX
Nirsevimab to Protect Infants and Young Children During RSV season, NYC, 2023–2024 buff.ly/4iBQKyP
#medsky #pedsky #IDsky 🛟
Two studies show more promising results for RSV drug nirsevimab (Beyfortus) buff.ly/4ikJ1ox
Phase 3 randomized clinical trial (MELODY) buff.ly/4ignwVX
Nirsevimab to Protect Infants and Young Children During RSV season, NYC, 2023–2024 buff.ly/4iBQKyP
#medsky #pedsky #IDsky 🛟
Studies show more promising results for RSV drug nirsevimab
buff.ly
December 6, 2024 at 3:36 AM
Good news!
Two studies show more promising results for RSV drug nirsevimab (Beyfortus) buff.ly/4ikJ1ox
Phase 3 randomized clinical trial (MELODY) buff.ly/4ignwVX
Nirsevimab to Protect Infants and Young Children During RSV season, NYC, 2023–2024 buff.ly/4iBQKyP
#medsky #pedsky #IDsky 🛟
Two studies show more promising results for RSV drug nirsevimab (Beyfortus) buff.ly/4ikJ1ox
Phase 3 randomized clinical trial (MELODY) buff.ly/4ignwVX
Nirsevimab to Protect Infants and Young Children During RSV season, NYC, 2023–2024 buff.ly/4iBQKyP
#medsky #pedsky #IDsky 🛟
RSV is the leading cause of infant hospitalizations in the US.
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants - PubMed
Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need f...
pubmed.ncbi.nlm.nih.gov
May 7, 2025 at 9:21 PM
RSV is the leading cause of infant hospitalizations in the US.
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
Nirsevimab (a monoclonal antibody) cuts RSV-related hospital stays in infants and reduces severity of other respiratory viruses. Fewer ICU visits, shorter stays—big win for babies and families.
pubmed.ncbi.nlm.nih.gov/40302169/
Study shows nirsevimab provides significant protection against RSV
Against severe RSV disease, nirsevimab had a very high efficacy of 84.6%.
www.cidrap.umn.edu/r...
Against severe RSV disease, nirsevimab had a very high efficacy of 84.6%.
www.cidrap.umn.edu/r...
March 10, 2025 at 8:11 PM
Study shows nirsevimab provides significant protection against RSV
Against severe RSV disease, nirsevimab had a very high efficacy of 84.6%.
www.cidrap.umn.edu/r...
Against severe RSV disease, nirsevimab had a very high efficacy of 84.6%.
www.cidrap.umn.edu/r...
🧵RFKJ and one of his ACIP picks, Robert Malone, appear to be getting ready to restrict the Respiratory Syncytial Virus (RSV) immunizations (nirsevimab and clesrovimab) saying there is a vast cover up of vaccine safety data.
As a pediatrician and CDC worker I have two questions for RFKJ about that:
As a pediatrician and CDC worker I have two questions for RFKJ about that:
September 5, 2025 at 9:40 PM
🧵RFKJ and one of his ACIP picks, Robert Malone, appear to be getting ready to restrict the Respiratory Syncytial Virus (RSV) immunizations (nirsevimab and clesrovimab) saying there is a vast cover up of vaccine safety data.
As a pediatrician and CDC worker I have two questions for RFKJ about that:
As a pediatrician and CDC worker I have two questions for RFKJ about that:
Very excited to see this work by my residency classmate calling for removal of race based guidance for Nirsevimab.
Race is a social construct, not a biological one.
Racism is the risk factor.
#MedSky #PedsSky
Race is a social construct, not a biological one.
Racism is the risk factor.
#MedSky #PedsSky
Race-Based Guidance and Nirsevimab
This Viewpoint discusses the current Advisory Committee on Immunization Practices and American Academy of Pediatrics race-based guidelines on the administration of nirsevimab and suggested race-consci...
jamanetwork.com
May 6, 2025 at 1:40 PM
💉🧵PSA 🚨 We don’t know for sure but are very worried RFKJ’s ACIP is about to restrict access to RSV monoclonal immunization for babies (nirsevimab and clesrovimab). If your baby is eligible, get them vaccinated asap. RSV season starts late Oct-early Nov. See below for immunization recommendation info
September 12, 2025 at 10:07 PM
💉🧵PSA 🚨 We don’t know for sure but are very worried RFKJ’s ACIP is about to restrict access to RSV monoclonal immunization for babies (nirsevimab and clesrovimab). If your baby is eligible, get them vaccinated asap. RSV season starts late Oct-early Nov. See below for immunization recommendation info
Analysis suggests nirsevimab cuts infant RSV hospitalizations 83%
Total RSV cases in children 12 months or younger were significantly lower in states with population-wide nirsevimab strategies.
www.cidrap.umn.edu/r...
Total RSV cases in children 12 months or younger were significantly lower in states with population-wide nirsevimab strategies.
www.cidrap.umn.edu/r...
January 21, 2026 at 9:38 PM
Analysis suggests nirsevimab cuts infant RSV hospitalizations 83%
Total RSV cases in children 12 months or younger were significantly lower in states with population-wide nirsevimab strategies.
www.cidrap.umn.edu/r...
Total RSV cases in children 12 months or younger were significantly lower in states with population-wide nirsevimab strategies.
www.cidrap.umn.edu/r...
In Ireland we probably averted about 500 newborn RSV hospitalizations once nirsevimab was introduced last year (~75% risk reduction). Uptake was > 80%, and that's what's threatened by these cynical safety concerns from the antivaxxers in the US government.
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
December 10, 2025 at 3:06 AM
In Ireland we probably averted about 500 newborn RSV hospitalizations once nirsevimab was introduced last year (~75% risk reduction). Uptake was > 80%, and that's what's threatened by these cynical safety concerns from the antivaxxers in the US government.
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
RSV research: Nirsevimab 80% effective against hospitalization www.cidrap.umn.edu/respiratory-...
RSV research: Nirsevimab 80% effective against hospitalization
www.cidrap.umn.edu
June 7, 2024 at 10:39 PM
RSV research: Nirsevimab 80% effective against hospitalization www.cidrap.umn.edu/respiratory-...
Universal nirsevimab slashes RSV infant hospitalizations, study suggests
Widespread immunization cut hospital admissions by 86%.
www.cidrap.umn.edu/r...
Widespread immunization cut hospital admissions by 86%.
www.cidrap.umn.edu/r...
January 13, 2026 at 10:19 PM
Universal nirsevimab slashes RSV infant hospitalizations, study suggests
Widespread immunization cut hospital admissions by 86%.
www.cidrap.umn.edu/r...
Widespread immunization cut hospital admissions by 86%.
www.cidrap.umn.edu/r...
Great to see evidence over two seasons showing the profound positive impact of nirsevimab on RSV hospitalizations in infants. Hospitalizations were reduced by 86% for season 1 and 55% in season 2 in Spain.
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective...
Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations
and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations
into the second season an...
www.thelancet.com
January 14, 2026 at 1:23 PM
Great to see evidence over two seasons showing the profound positive impact of nirsevimab on RSV hospitalizations in infants. Hospitalizations were reduced by 86% for season 1 and 55% in season 2 in Spain.
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
RFK.Jr's FDA is trying to ban this therapy in the US!
www.thelancet.com/journals/lan...
We're back, baby! #altMMWR returns after 7 weeks
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
Nirsevimab Effectiveness Against Intensive Care Unit ...
This report describes a multicenter case-control investigation that found nirsevimab was 80% effective at preventing RSV-associated ICU admissions among infants.
www.cdc.gov
November 20, 2025 at 11:44 PM
We're back, baby! #altMMWR returns after 7 weeks
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
Our first paper looks at nirsevimab's effectiveness against RSV-related intensive care unit admissions among babies 👶
Tl;dr: it works! ~80% effectiveness for both of these outcomes
www.cdc.gov/mmwr/volumes...
For our fellow nerds,🧵👇
Nirsevimab Reduces RSV-related Hospitalizations 80% in High-Risk Infants jamanetwork.com/journals/jam...
Nirsevimab in High-Risk Infants in an RSV Prevention Strategy
This case-control study evaluates the association of nirsevimab with the prevention of respiratory syncytial virus (RSV) infection among at-risk infants after implementation of a universal immunization strategy in Chile.
jamanetwork.com
April 11, 2026 at 3:17 AM
Nirsevimab Reduces RSV-related Hospitalizations 80% in High-Risk Infants jamanetwork.com/journals/jam...
Reduced RSV Hospitalizations in Infants Treated with Nirsevimab respiratory-therapy.com/disorders-di...
Reduced RSV Hospitalizations in Infants Treated with Nirsevimab
Researchers examined the effectiveness of nirsevimab during the 2024–2025 RSV season using a large, multi-institutional dataset.
respiratory-therapy.com
October 1, 2025 at 10:36 AM
Reduced RSV Hospitalizations in Infants Treated with Nirsevimab respiratory-therapy.com/disorders-di...
Studies: RSV prevention strategies—especially nirsevimab—may cut infant hospitalizations
The drug was 81% effective against RSV hospitalization.
www.cidrap.umn.edu/s...
The drug was 81% effective against RSV hospitalization.
www.cidrap.umn.edu/s...
January 2, 2026 at 8:12 PM
Studies: RSV prevention strategies—especially nirsevimab—may cut infant hospitalizations
The drug was 81% effective against RSV hospitalization.
www.cidrap.umn.edu/s...
The drug was 81% effective against RSV hospitalization.
www.cidrap.umn.edu/s...
Chile reduce drásticamente hospitalizaciones y muertes por virus sincicial gracias a campaña con Nirsevimab
Chile reduce drásticamente hospitalizaciones y muertes por virus sincicial gracias a campaña con Nirsevimab
El análisis reveló, además, una caída del 76% en hospitalizaciones por infecciones respiratorias graves y un 85% de efectividad para evitar ingresos a UCI pediátricas.
www.24horas.cl
June 18, 2025 at 9:24 PM
Chile reduce drásticamente hospitalizaciones y muertes por virus sincicial gracias a campaña con Nirsevimab
Ziresovir sind in der Pipeline, monoklonale Antikörper wie Palivizumab und Nirsevimab stehen bereits zur Verfügung.
4/9
4/9
February 10, 2026 at 11:13 AM
Ziresovir sind in der Pipeline, monoklonale Antikörper wie Palivizumab und Nirsevimab stehen bereits zur Verfügung.
4/9
4/9
In the latest from Sensible Medicine, a name wearing out the irony meter to a degree similar to Democratic People’s Republic of Korea, they come out against universal RSV prophylaxis for infants.
RSV is the leading cause of hospitalization in kids under 2 and Nirsevimab has 90+% effectiveness.
RSV is the leading cause of hospitalization in kids under 2 and Nirsevimab has 90+% effectiveness.
December 30, 2024 at 3:17 AM
In the latest from Sensible Medicine, a name wearing out the irony meter to a degree similar to Democratic People’s Republic of Korea, they come out against universal RSV prophylaxis for infants.
RSV is the leading cause of hospitalization in kids under 2 and Nirsevimab has 90+% effectiveness.
RSV is the leading cause of hospitalization in kids under 2 and Nirsevimab has 90+% effectiveness.
#DragiWebdo n°483 : Calendrier vaccinal (Reco), pharmaciens, VRS (nirsevimab, vaccin), Facteur V Leiden, semaglutide/MASH, audition, diabète, insuffisance surrénale, système de santé privé
www.medicalement-geek.com/2025/05/drag...
www.medicalement-geek.com/2025/05/drag...
Dragi Webdo n°483 : Calendrier vaccinal (Reco), pharmaciens, VRS (nirsevimab, vaccin), F5 Leiden, semaglutide/MASH, audition, diabète, insuffisance surrénale, système de santé privé
Dragi Webdo n°483 : Calendrier vaccinal , pharmaciens, VRS (nirsevimab), Leiden, MASH, audition, diabète, surrénalienne, privé
www.medicalement-geek.com
May 4, 2025 at 6:58 PM
#DragiWebdo n°483 : Calendrier vaccinal (Reco), pharmaciens, VRS (nirsevimab, vaccin), Facteur V Leiden, semaglutide/MASH, audition, diabète, insuffisance surrénale, système de santé privé
www.medicalement-geek.com/2025/05/drag...
www.medicalement-geek.com/2025/05/drag...
“The researchers found that nirsevimab reduced risk for RSV-LRTI-related hospitalization in the 2023 and 2024 birth cohorts relative to nonreceipt. Nirsevimab had an effectiveness of 66% to 72%.” www.infectiousdiseaseadvisor.com/news/nirsevi...
Nirsevimab Immunization Reduces RSV-LRTI Hospitalization
Nirsevimab immunization effectively decreases the risk for RSV-related LRTI hospitalizations in an infant's first year.
www.infectiousdiseaseadvisor.com
October 1, 2026 at 1:28 PM
“The researchers found that nirsevimab reduced risk for RSV-LRTI-related hospitalization in the 2023 and 2024 birth cohorts relative to nonreceipt. Nirsevimab had an effectiveness of 66% to 72%.” www.infectiousdiseaseadvisor.com/news/nirsevi...
⭐️Very good news - Nirsevimab which can reduce RSV hospitalizations by over 80% will be available for newborns this winter season in Austria
www.sn.at/panorama/oes...
www.sn.at/panorama/oes...
Demnächst Gratis-RSV-Prophylaxe für Neugeborene möglich
Demnächst ist ein vorbeugendes Medikament gegen das Respiratorische Synzytial-Virus (RSV) für alle Neugeborenen in Österreich verfügbar. Die passive Immunisierung mit Beyfortus (Nirsevimab) wird noch ...
www.sn.at
November 20, 2024 at 10:48 AM
⭐️Very good news - Nirsevimab which can reduce RSV hospitalizations by over 80% will be available for newborns this winter season in Austria
www.sn.at/panorama/oes...
www.sn.at/panorama/oes...
More evidence, now from Ireland, that infant immunisation with nirsevimab substantially reduced risks for hospitalisation due to RSV. Feedback very welcome, as well as suggestions for an eventual home.
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
Surveillance-based estimation of the impact of introducing a pathfinder programme for nirsevimab immunisation in Ireland on infant hospitalisations due to respiratory syncytial virus in 2024/2025
Respiratory syncytial virus (RSV) presents a significant health risk to young infants and substantially burdens already stretched health systems every winter. Ireland launched a RSV immunisation pathf...
www.medrxiv.org
April 25, 2025 at 4:09 PM
More evidence, now from Ireland, that infant immunisation with nirsevimab substantially reduced risks for hospitalisation due to RSV. Feedback very welcome, as well as suggestions for an eventual home.
www.medrxiv.org/content/10.1...
www.medrxiv.org/content/10.1...
Nirsevimab is a GD miracle.
"They asked me if I had a will prepared for my baby... Before this happened, I probably would have declined an RSV vaccine."
After a *very* close call, Megan encourages other moms to vaccinate. www.voicesforvaccines.org/i-wish-there...
After a *very* close call, Megan encourages other moms to vaccinate. www.voicesforvaccines.org/i-wish-there...
I Wish I’d Had the RSV Vaccine
I thought my baby just had a cold. Within a matter of hours she was in the PICU because of this virus.
www.voicesforvaccines.org
December 20, 2024 at 10:10 PM
Nirsevimab is a GD miracle.